Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 known ✓ | P00918 | 2/20 | 0.39 |
| ▸ | MAOA known ✓ | P21397 | 1/20 | 0.33 |
| ▸ | MAOB known ✓ | P27338 | 1/20 | 0.33 |
| ▸ | HDAC3 known ✓ | O15379 | 1/20 | 0.33 |
| ▸ | HDAC1 known ✓ | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 known ✓ | Q92769 | 1/20 | 0.33 |
| ▸ | HDAC8 known ✓ | Q9BY41 | 1/20 | 0.33 |
| ▸ | HDAC6 known ✓ | Q9UBN7 | 1/20 | 0.33 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | PTPRC | P08575 | 2/20 | 0.36 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.36 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL31480795 | 1.00 | CA2 (0.39) | CA2CA12CA14DGAT1CYP2D6 | |
| SCHEMBL410255 | 0.98 | CA2 (0.40) | CA2CA12CA14DGAT1CYP2D6 | |
| SCHEMBL20829083 | 0.85 | RECQL (0.41) | CA2CA12CA14DGAT1CYP2D6 | |
| SCHEMBL17837047 | 0.84 | CA2 (0.38) | CA2CA12CA14DGAT1CYP2D6 | |
| SCHEMBL6982402 | 0.81 | CYP3A4 (0.38) | CA2CA12CA14CYP2D6PTPRC | |
| SCHEMBL8150221 | 0.80 | CA2 (0.36) | CA2CA12CA14DGAT1CYP2D6 | |
| SCHEMBL23894059 | 0.80 | CA2 (0.41) | CA2CA12CA14DGAT1CYP2D6 | |
| SCHEMBL783009 | 0.80 | CA2 (0.41) | CA2CA12CA14DGAT1CYP2D6 | |
| Hydrochloric Acid SCHEMBL18770548 | 0.79 | CA12 (0.38) | CA2CA12CA14DGAT1CYP2D6 | |
| SCHEMBL16256489 | 0.79 | GAA (0.32) | CA2CA12CA14GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 407 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118164974-B | Lipid-droplet protein photoaffinity labeling probe and preparation method and application thereof | 山东大学 | 2025-03-18 | — | — | CN | claimed |
| CN-118164974-A | Lipid-droplet protein photoaffinity labeling probe and preparation method and application thereof | 山东大学 | 2024-06-11 | — | — | CN | claimed |
| CN-111849460-B | Near-infrared ratiometric fluorescent probe for detecting biological mercaptan based on fluorescence resonance energy transfer and preparation and application thereof | 嘉兴学院 | 2022-04-22 | — | — | CN | claimed |
| CN-111849460-A | Near-infrared ratiometric fluorescent probe for detecting biological mercaptan based on fluorescence resonance energy transfer and preparation and application thereof | 嘉兴学院 | 2020-10-30 | — | — | CN | claimed |
| US-12630531-B2 | Quinazoline-2,4-diamine derivative and pharmaceutical composition for preventing or treating cancer comprising same as active ingredient | OMIC SMAP INC. (KR) | 2026-05-19 | — | — | US | disclosed |
| EP-4678652-A1 | METHOD FOR PRODUCING CYCLIC PEPTIDE COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2026-01-14 | — | — | EP | disclosed |
| US-12415789-B2 | Macrocycles comprising a 4-amido-2,4-pentadienoate moiety for the treatment of hypoxic cancers | AARHUS UNIVERSITET (DK) | 2025-09-16 | — | — | US | disclosed |
| US-12410212-B2 | Cyclic compound having selective KRAS inhibitory effect on HRAS and NRAS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-09-09 | — | — | US | disclosed |
| EP-4603105-A1 | PHARMACEUTICAL COMPOSITION CONTAINING CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT AGAINST HRAS AND NRAS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-08-20 | — | — | EP | disclosed |
| US-12390437-B2 | Itaconic acid derivatives and uses thereof intreating an inflammatory disease or a disease associated with an undesirable immune response | SITRYX THERAPEUTICS LIMITED (GB) | 2025-08-19 | — | — | US | disclosed |
| US-12384776-B2 | Compounds and uses thereof | FOGHORN THERAPEUTICS INC. (US) | 2025-08-12 | — | — | US | disclosed |
| EP-4592308-A1 | CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-07-30 | — | — | EP | disclosed |
| WO-2000044709-A2 | ACETYLENIC α-AMINO ACID-BASED SULFONAMIDE HYDROXAMIC ACID TACE INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 2000-08-03 | — | — | WO | disclosed |
| US-6093731-A | Isoquinolines | PFIZER INC. | 2000-07-25 | — | — | US | disclosed |
| WO-2000005214-A2 | ISOQUINOLINES AS UROKINASE INHIBITORS | PFIZER INC. (US) | 2000-02-03 | — | — | WO | disclosed |
| WO-1999021845-A2 | 4-AMINOTHIAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF CYCLIN-DEPENDENT KINASES | AGOURON PHARMACEUTICALS, INC. (US) | 1999-05-06 | — | — | WO | disclosed |
| CN-1190389-A | Novel farnesyl transferase inhibitors, process for their preparation and pharmaceutical compositions containing them | RHONE POULENC RORER SA (FR) | 1998-08-12 | — | — | CN | disclosed |
| EP-0789683-A1 | FLUOROBUTENYL ESTERS AND THEIR USE FOR CONTROLLING ANIMAL PESTS | BAYER AG (DE) | 1997-08-20 | — | — | EP | disclosed |
| WO-1996014289-A1 | FLUOROBUTENYL ESTERS AND THEIR USE FOR CONTROLLING ANIMAL PESTS | BAYER AKTIENGESELLSCHAFT (DE) | 1996-05-17 | — | — | WO | disclosed |
| WO-1992016549-A1 | PARASUBSTITUTED PHENYLALANINE DERIVATES | PENTAPHARM AG (CH) | 1992-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12384776-B2 | Compounds and uses thereof | VHL, TFEB, BECN1 | CA2 4669/4885MAOA 2662/4885MAOB 1651/4885 |
| US-12410212-B2 | Cyclic compound having selective KRAS inhibitory effect on HRAS and NRAS | KRAS, HRAS, NRAS | CA2 2914/4885MAOA 4872/4885MAOB 4879/4885 |
| US-12390437-B2 | Itaconic acid derivatives and uses thereof intreating an inflammatory disease or a disease associated with an undesirable immune response | IL1R1, IL1B, IL1A | CA2 2440/4885MAOA 3884/4885MAOB 4458/4885 |
| US-12630531-B2 | Quinazoline-2,4-diamine derivative and pharmaceutical composition for preventing or treating cancer comprising same as active ingredient | EHMT2, EHMT1, HNMT | CA2 1631/4885MAOA 2564/4885MAOB 2948/4885 |
| US-12415789-B2 | Macrocycles comprising a 4-amido-2,4-pentadienoate moiety for the treatment of hypoxic cancers | DLD, HIF1A, DPYD | CA2 1246/4885MAOA 2537/4885MAOB 1794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.